Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 13/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435576 | 0.88 | PRKDC (1.00) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL5661282 | 0.85 | PRKDC (0.79) | PRKDCMTOR | |
| SCHEMBL10092321 | 0.85 | PRKDC (1.00) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL13435575 | 0.84 | PRKDC (1.00) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL3537867 | 0.78 | PRKDC (1.00) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL13346529 | 0.77 | PRKDC (1.00) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL3536365 | 0.77 | PRKDC (1.00) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL31060462 | 0.76 | PRKDC (0.71) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL3542914 | 0.74 | PRKDC (0.62) | PRKDCMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL3535168 | 0.74 | PRKDC (0.69) | PRKDCMTORPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | PRKDC 92/4885MTOR 803/4885PIK3CB 575/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | PRKDC 212/4885MTOR 620/4885PIK3CB 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.